Menu
← Oncology Approval Tracker
FDA DECISION ·
Lumakras + Vectibix
sotorasib + panitumumab · Amgen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with FDA-test-confirmed KRAS G12C-mutated metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The combination pairs a KRAS G12C inhibitor with EGFR blockade in previously treated colorectal cancer.
What research teams should watch
Confirm KRAS G12C status and capture exposure to all three required chemotherapy components before enrollment screening.
PRIMARY RECORDS